Denali Therapeutics Inc.
A compact read across the newest available filing, institutional, insider, company-event, 13F, fundamental, and price evidence. Each item keeps its own reporting window; the evidence is not collapsed into a buy or sell recommendation.
TROW-IM Reported accumulation in DNLI. Reported shares changed +7,659,771. Ownership changed +0.00 percentage points. Fast amendment; filing trigger not confirmed. Price fell since disclosure despite accumulation.
Source: SC 13G/ABroad accumulation. 3 accumulating across 3 comparable institutions.
Source: Schedule 13 researchRecent Forms 3/4/5 activity is available, with no non-amendment non-derivative SEC-coded P/S transactions in the rolling 90-day window. Amendments are shown in the filing evidence but excluded from rolling activity totals.
Source: SEC Forms 3/4/5Recent close is 85% through its reported 52-week range; +90.2% over one year.
Source: Stored historical price seriesConfidence: High. Confidence measures the completeness of the ownership comparison, not the probability that the stock will move in a particular direction.
The research summary above gives the current read. This section shows the dated holder-level evidence behind it.
Each row compares that institution's newest reported position with its own prior position. As of is the reported position date; filed is when the disclosure reached the SEC.
Latest reported position for each institution compared only with that institution’s previous reported position. Direction uses reported share count when available; ownership percentage is shown separately.
Reported Section 16 ownership activity. Rolling purchase/sale totals use non-derivative SEC transaction codes P and S only; amendments remain visible but are excluded from those totals.
| Date | Reporting owner | Code | Security | Shares | Price | Ownership | Filed |
|---|---|---|---|---|---|---|---|
| Jun 3, 2026 | FLATLEY JAY T | AGrant, award, or other acquisition · derivative | Stock Option (right to buy) | 19.2K | $0.00 | Direct | Jun 5, 2026 |
| Jun 3, 2026 | FLATLEY JAY T | AGrant, award, or other acquisition | Common Stock | 6.4K | $0.00 | Direct | Jun 5, 2026 |
| Jun 3, 2026 | Klein Peter S | AGrant, award, or other acquisition · derivative | Stock Option (right to buy) | 19.2K | $0.00 | Direct | Jun 5, 2026 |
| Jun 3, 2026 | Klein Peter S | AGrant, award, or other acquisition | Common Stock | 6.4K | $0.00 | Direct | Jun 5, 2026 |
| Jun 3, 2026 | Krognes Steve E. | AGrant, award, or other acquisition · derivative | Stock Option (right to buy) | 19.2K | $0.00 | Direct | Jun 5, 2026 |
| Jun 3, 2026 | Krognes Steve E. | AGrant, award, or other acquisition | Common Stock | 6.4K | $0.00 | Direct | Jun 5, 2026 |
| Jun 3, 2026 | Schenkein David P | AGrant, award, or other acquisition · derivative | Stock Option (right to buy) | 19.2K | $0.00 | Direct | Jun 5, 2026 |
| Jun 3, 2026 | Schenkein David P | AGrant, award, or other acquisition | Common Stock | 6.4K | $0.00 | Direct | Jun 5, 2026 |
| Jun 3, 2026 | Thornberry Nancy | AGrant, award, or other acquisition · derivative | Stock Option (right to buy) | 19.2K | $0.00 | Direct | Jun 5, 2026 |
| Jun 3, 2026 | Thornberry Nancy | AGrant, award, or other acquisition | Common Stock | 6.4K | $0.00 | Direct | Jun 5, 2026 |
| Jun 3, 2026 | Van Hauwermeiren Timothy | AGrant, award, or other acquisition · derivative | Stock Option (right to buy) | 19.2K | $0.00 | Direct | Jun 5, 2026 |
| Jun 3, 2026 | Van Hauwermeiren Timothy | AGrant, award, or other acquisition | Common Stock | 6.4K | $0.00 | Direct | Jun 5, 2026 |
| Jun 3, 2026 | Cook Jennifer E. | AGrant, award, or other acquisition · derivative | Stock Option (right to buy) | 19.2K | $0.00 | Direct | Jun 5, 2026 |
| Jun 3, 2026 | Cook Jennifer E. | AGrant, award, or other acquisition | Common Stock | 6.4K | $0.00 | Direct | Jun 5, 2026 |
| Jun 3, 2026 | BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | AGrant, award, or other acquisition · derivative | Non- Qualified Stock Option (right to buy) | 19.2K | $0.00 | Indirect | Jun 5, 2026 |
| Jun 3, 2026 | BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | AGrant, award, or other acquisition · derivative | Non-Qualified Stock Option (right to buy) | 19.2K | $0.00 | Indirect | Jun 5, 2026 |
| Jun 3, 2026 | BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | AGrant, award, or other acquisition | Common Stock | 6.4K | $0.00 | Indirect | Jun 5, 2026 |
| Jun 3, 2026 | BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | AGrant, award, or other acquisition | Common Stock | 6.4K | $0.00 | Indirect | Jun 5, 2026 |
Dated price context from the historical market series already collected for this security.
Returns are close-to-close price changes. Volatility and drawdown are factual historical context, not recommendations.
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.
| Holder | Observed / filed | Activity | Shares | Ownership | Observation | Filing | Latest | Since filing |
|---|
Compare DNLI with other securities showing similar institutional activity or recent accumulation across several tracked institutions.